Research Topics
Species | John D HaleySummaryAffiliation: OSI Pharmaceuticals Country: USA Publications
| Collaborators
|
Detail Information
Publications
Identification and characterization of mechanistically distinct inducers of gamma-globin transcriptionJohn D Haley
OSI Pharmaceuticals Inc, Farmingdale, NY 11735, USA
Biochem Pharmacol 66:1755-68. 2003..This screening methodology successfully identifies active compounds for further mechanistic and preclinical evaluation as potential therapeutic agents for sickle cell anemia...
Phosphotyrosine signaling networks in epidermal growth factor receptor overexpressing squamous carcinoma cellsApril Thelemann
OSI Pharmaceuticals, Inc, Farmingdale, NY 11735, USA
Mol Cell Proteomics 4:356-76. 2005..The functional interactions between IGF-1 receptor, lysophosphatidic acid (LPA) signaling, and EGF receptor were observed, both direct and/or indirectly on phospho-Akt, phospho-Erk1/2, and phospho-ribosomal S6...- A systems view of epithelial-mesenchymal transition signaling statesStuart Thomson
Translational Research, OSI Pharmaceuticals Inc, 1 Bioscience Park Drive, Farmingdale, NY 11735, USA
Clin Exp Metastasis 28:137-55. 2011..Correlation to stem cell, EMT, invasion and metastasis datasets revealed the greatest similarity with normal and cancerous breast stem cell populations, CD49f(hi)/EpCAM(-/lo) and CD44(hi)/CD24(lo), respectively... 
Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancyStuart Thomson
Department of Translational Research, OSI Pharmaceuticals Inc, 1 Bioscience Park Drive, Farmingdale, NY 11735, USA
Clin Exp Metastasis 25:843-54. 2008..The findings of kinase switching and acquired PDGFR and FGFR signaling suggest investigation of new inhibitor combinations to target NSCLC metastases...- Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibitionElizabeth Buck
OSI Pharmaceuticals, Inc, 1 Bioscience Park Drive, Farmingdale, NY 11735, USA
Mol Cancer Ther 6:532-41. 2007.... - Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumorsElizabeth Buck
OSI Pharmaceuticals, 1 Bioscience Park Drive, Farmingdale, NY 11787, USA
Mol Cancer Ther 5:2676-84. 2006..These results suggest that combining rapamycin with erlotinib might be clinically useful to enhance response to erlotinib... - Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptorsElizabeth Buck
Translational Research, Cancer Biology, OSI Pharmaceuticals, Farmingdale, New York 11735, USA
Cancer Res 68:8322-32. 2008..Collectively, these data show that resistance to inhibition of MEK, mTOR, and EGFR is associated with enhanced IGF-IR-directed Akt signaling, where all affect feedback loops converging at the level of IRS-1... - Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivityElizabeth Buck
Department of Translational Research, OSI Pharmaceuticals, Inc, 1 Bioscience Park Drive, Farmingdale, NY 11787, USA
Mol Cancer Ther 5:2051-9. 2006..These studies suggest that HER-3 could be used as a biomarker to select patients who are most likely to respond to erlotinib therapy... - Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibitionStuart Thomson
Departments of Translational Research and Oncology Research, OSI Pharmaceuticals, Inc, Farmingdale, NY 11735, USA
Cancer Res 65:9455-62. 2005..These data suggest that EMT may be a general biological switch rendering non-small cell lung tumors sensitive or insensitive to EGFR inhibition... - Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitionsSharon Barr
OSI Pharmaceuticals Inc, 1 Bioscience Park Dr, Farmingdale, NY 11735, USA
Clin Exp Metastasis 25:685-93. 2008..The interaction between EGFR and the multiple signaling nodes which regulate EMT suggest that the combination of an EGFR inhibitor and other molecular targeted agents may offer a novel approach to controlling metastasis... - Peptide, domain, and DNA affinity selection in the identification and quantitation of proteins from complex biological samplesFilippo Petti
Translational Research, OSI Oncology, Farmingdale, NY 11735, USA
Anal Biochem 356:1-11. 2006 - Temporal quantitation of mutant Kit tyrosine kinase signaling attenuated by a novel thiophene kinase inhibitor OSI-930Filippo Petti
OSI Pharmaceuticals, Inc, 1 Bioscience Park Drive, Farmingdale, NY 11735, USA
Mol Cancer Ther 4:1186-97. 2005.... - Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinibKendall D Carey
Department of Translational Oncology, Genentech, Inc, South San Francisco, CA 94080, USA
Cancer Res 66:8163-71. 2006..These findings suggest that EGFR somatic mutations directly influence both erlotinib sensitivity and cellular transformation...